EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access

Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients

Jung-Joon Cha iD, Yonghoon Shin iD, Hyung Joon Joo iD, Jae Hyoung Park iD, Cheol Woong Yu iD, Pil Hyung Lee iD, Seung Whan Lee iD, Cheol Whan Lee iD, Jae Youn Moon iD, Jong-Young Lee iD, Jung-Sun Kim iD, Jae Suk Park iD und 1 weitere

Journal of the American Heart Association · 07.07.2026 · 15 (13)

DOI: 10.1161/jaha.125.048711 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von Jung-Joon Cha und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital Korea University College of Medicine Seoul Republic of Korea. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ezetimibe, Cholesterol, LDL, Rosuvastatin Calcium. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐intensity statins are recommended for secondary prevention in atherosclerotic cardiovascular disease (ASCVD), but older adults frequently experience tolerability issues and adverse metabolic effects. Moderate‐intensity statin plus ezetimibe can achieve substantial low‐density lipoprotein cholesterol lowering, yet randomized data comparing metabolic and safety outcomes versus high‐intensity statins in older patients remain limited.

Methods

This subgroup analysis of the randomized SaveSAMS (Effects of High‐Dose Statin Versus Low‐Dose Statin Plus Ezetimibe on SAMS and on Reaching Target LDL‐Cholesterol Levels Among Older Patients With ASCVD) trial included patients aged ≥70 years with established ASCVD assigned to high‐intensity statin monotherapy (rosuvastatin 20 mg) or a moderate‐intensity statin plus ezetimibe (rosuvastatin 5 mg/ezetimibe 10 mg). Among 318 patients (monotherapy, n=168; combination, n=150), 6‐month changes in lipid parameters, metabolic biomarkers, and safety end points were compared.

Results

Both strategies significantly improved lipid profiles. Combination therapy achieved greater non–high‐density lipoprotein cholesterol reduction (Δ −76.0 versus −66.0 mg/dL; P =0.047) and attenuated statin‐associated increases in lipoprotein(a) (Δ +0.1 versus +1.2 mg/dL; P =0.033). Statin‐associated muscle symptoms occurred less frequently with combination therapy (0.7% versus 5.4%; P =0.021). New‐onset diabetes did not differ significantly between groups (5.1% versus 14.5%; P =0.065), while changes in glycemic markers were similar. Low‐density lipoprotein cholesterol target attainment (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeCholesterol, LDLRosuvastatin CalciumAnticholesteremic AgentsAtherosclerosisSecondary PreventionDyslipidemiasHumansAgedFemaleMaleTreatment OutcomeDrug Therapy, CombinationBiomarkersAge FactorsAged, 80 and overLipoprotein(a)

Stichwörter der Autor:innen

ezetimibeglucose metabolismlipoprotein(a)non–HDL cholesterololderstatin

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeCholesterol, LDLRosuvastatin CalciumBiomarkersAnticholesteremic AgentsLipoprotein(a)

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital Korea University College of Medicine Seoul Republic of Korea.
  • Department of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea.
  • Department of Cardiology, CHA Bundang Medical Center CHA University Seongnam Republic of Korea.
  • Department of Internal Medicine, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Seoul Republic of Korea.
  • Division of Cardiology, Severance Hospital Yonsei University College of Medicine Seoul Republic of Korea.
  • Division of Cardiology Incheon Sejong Hospital Incheon Republic of Korea.

ORCID-Profile: Jung-Joon Cha, Yonghoon Shin, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Pil Hyung Lee, Seung Whan Lee, Cheol Whan Lee, Jae Youn Moon, Jong-Young Lee, Jung-Sun Kim, Jae Suk Park, Soon Jun Hong

Zitieren

APA

Cha, J. J., Shin, Y., Joo, H. J., Park, J. H., Yu, C. W., Lee, P. H., Lee, S. W., Lee, C. W., Moon, J. Y., Lee, J. Y., Kim, J. S., Park, J. S., & Hong, S. J. (2026). Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.048711

Vancouver

Cha JJ, Shin Y, Joo HJ, Park JH, Yu CW, Lee PH, et al. Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.048711

BibTeX
@article{Cha2026,
  author = {Cha, Jung-Joon and Shin, Yonghoon and Joo, Hyung Joon and Park, Jae Hyoung and Yu, Cheol Woong and Lee, Pil Hyung and Lee, Seung Whan and Lee, Cheol Whan and Moon, Jae Youn and Lee, Jong-Young and Kim, Jung-Sun and Park, Jae Suk and Hong, Soon Jun},
  title = {Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {13},
  doi = {10.1161/jaha.125.048711}
}
Kostenlos starten →